Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > New Press Release - Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
View:
Post by PressRelease on May 09, 2024 7:00am

New Press Release - Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Comment by Noteable on May 09, 2024 8:48am
This press release now has the world learning what we know --- that ONCY's drug platform pelareorep in combination with immune checkpoint inhibitors is effective in the expanded treatment of the orphan/rare disease of pancreatic cancer.  We already know that ONCY's pelareorep is ready for a Phase registration study in the for the orphan disease and unmet treatment need of metastatic ...more  
Comment by Noteable on May 09, 2024 8:57am
Since ONCY is moving into a registration study in the orphan/rare disease of pancreatic cancer, ONCY's is on the doorstep of an Accelerated Approval for this indication. ONCY just has to step up and request the Accelerated Approval from the FDA, which could be what the requested Type C meeting with the FDA is partially about.
Comment by ENEMENEMYNEMO on May 09, 2024 9:04am
Hey Mr Note Pumper, This is not a  registrational study, you've got to wait 3+ yrs for that.  ""If the mFOLFIRINOX combination shows a compelling efficacy signal, this therapeutic approach could also be advanced to a registration-enabling study, providing two opportunities for pelareorep-based treatment to benefit pancreatic cancer patients,"
Comment by ENEMENEMYNEMO on May 09, 2024 9:07am
This will however give Matt  the opportunity to dilute the sp with further offerings though!
Comment by Azzak34 on May 09, 2024 9:09am
Oof Nemo must need a few extra quid this week, working hard this morning!!  This is a completely new opportunity. Panc and Breast are still carrying on. You have no idea what you're doing here do you? 
Comment by ENEMENEMYNEMO on May 09, 2024 9:17am
Nah just a day off and it's raining.  Wait somebody will pay me for this??
Comment by ENEMENEMYNEMO on May 09, 2024 9:19am
I guess the proofs in the puddin'.  Let's see where the sp is tomorrow?
Comment by Azzak34 on May 09, 2024 9:20am
Yeah you get paid per post and they couldn't care less about spelling or general grammar. See if Bucky can hook you up. 
Comment by ENEMENEMYNEMO on May 09, 2024 9:33am
You are such a dryshite ...are you Canfan?? Cus he certainly has not been posting ad nauseam as per past experience.
Comment by Azzak34 on May 09, 2024 10:03am
Haha don't get upset babe, just get better.  He's a 2/3 per week type of poster. I'm more reactive. 
Comment by ENEMENEMYNEMO on May 09, 2024 10:06am
Rager
Comment by Noteable on May 09, 2024 9:07am
It's apparent that some who post here can't understand what's written regarding ONC's Phase 3 registration studiy in pancreatic cancer and the Accelerated Approval implementation.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities